ProKidney Analyst Price Targets - Benzinga

ProKidney Corp

PROKNASDAQ

Trade with Public

Trade with Public

$1.66

0.095.73%

Ult. Agg.: Oct 8, 6:12 PM

$1.64

0.074.46%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

ProKidney Analyst Price Targets - Benzinga

ProKidney Analyst Price Targets

Wall Street analyst price targets and consensus rating for ProKidney (PROK).

Price Target Range — 7 Quarters

Analyst Consensus — 7 Analysts

5Buy

1Hold

1Sell

Consensus RatingBuy# Analysts7Avg. Consensus PT$7Upside to Avg. PT+300.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 18, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$12
Dec 16, 2025	HC Wainwright & Co.	Joseph Pantginis	Initiate	Buy	$12
Jul 15, 2025	UBS	Eliana Merle	PT Raise	Buy	$4→$8
Jul 14, 2025	Guggenheim	Vamil Divan	PT Raise	Buy	$6→$7
Jul 9, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$6→$9
Jun 30, 2025	B of A Securities	Jason Gerberry	Downgrade	Neutral→Underperform	$3→$1
Sep 30, 2024	JP Morgan	Anupam Rama	Initiate	Neutral	—
Sep 10, 2024	Guggenheim	Vamil Divan	Initiate	Buy	$6
Sep 4, 2024	B of A Securities	Jason Gerberry	PT Cut	Neutral	$4→$3
Jun 10, 2024	Jefferies	Kelly Shi	PT Cut	Buy	$15→$6
May 29, 2024	B of A Securities	Jason Gerberry	PT Raise	Neutral	$3→$4
Mar 7, 2024	Morgan Stanley	Judah Frommer	Assumes	Equal-Weight	$3
Jan 2, 2024	B of A Securities	Jason Gerberry	Downgrade	Buy→Neutral	$8→$2

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy and maintains $12 price target.

Benzinga Newsdesk

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
UBS Maintains Buy on ProKidney, Raises Price Target to $8

UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on ProKidney, Raises Price Target to $7

Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on ProKidney, Raises Price Target to $7

Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.

Benzinga Newsdesk